CEFOTAXIME AND AMINOGLYCOSIDE TREATMENT OF MENINGITIS CAUSED BY GRAM-NEGATIVE ENTERIC ORGANISMS

被引:30
作者
KAPLAN, SL [1 ]
PATRICK, CC [1 ]
机构
[1] BAYLOR UNIV, DEPT PEDIAT, MYERS BLACK SECT PEDIAT INFECT DIS, HOUSTON, TX 77030 USA
关键词
Cefotaxime; Gram-negative entertics; Meningitis;
D O I
10.1097/00006454-199011000-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We reviewed cases of Gram-negative enteric bacillary meningitis in infants and children treated with cefotaxime at Texas Children’s Hospital from January, 1984, through June, 1989. Seventeen of 20 children had an underlying condition predisposing to the development of meningitis. The etiologic organisms in these 20 children (2 days to 12 years old; median, 12 days old) were Klebsiella sp, 9; Escherichia coli, 4; Enterobacter cloacae, 3; Citrobacter diversus, 2; other, 2. With the exception of one isolate of Acinetobacter, all isolates were susceptible to cefotaxime. In addition to cefotaxime 17 children received an aminoglycoside intravenously. Children with meningitis caused by Klebsiella sp. or non-Kliebsiella organisms received cefotaxime for 31 ± 14 and 37 ± 17 days, respectively. Aminoglycosides were administered for 16 ± 10 days in both groups. Five children in each group also received intraventricular doses (1 to 25) of an aminoglycoside (9) or colistimethate (1). The mean durations of positive lumbar, ventricular cerebrospinal fluid or brain abscess cultures were 5.8 ± 4.7 and 7.2 ± 5.0 days after start of therapy in the Klebsiella and non- Klebsiella meningitis patients, respectively. Only three children were normal at the time of discharge or follow-up. Gram-negative enteric meningitis remains difficult to treat despite the excellent in vitro activity of cefotaxime against Gram-negative enterics, in part as a result of the predisposing conditions resulting in the development of this infection. © 1990 by Williams and Wilkins.
引用
收藏
页码:810 / 814
页数:5
相关论文
共 26 条
[1]   PHARMACOKINETICS AND CLINICAL-EVALUATION OF CEFOTAXIME IN CHILDREN SUFFERING WITH PURULENT-MENINGITIS [J].
BEGUE, P ;
FLORET, D ;
MALLET, E ;
RAYNAUD, EJ ;
SAFRAN, C ;
SARLANGUES, J ;
TEYSSIER, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 :161-165
[2]  
BELOHRADSKY BH, 1980, LANCET, V1, P61
[3]   MULTIPLY RESISTANT HAEMOPHILUS-INFLUENZAE TYPE-B CAUSING MENINGITIS - COMPARATIVE CLINICAL AND LABORATORY STUDY [J].
CAMPOS, J ;
GARCIATORNEL, S ;
GAIRI, JM ;
FABREGUES, I .
JOURNAL OF PEDIATRICS, 1986, 108 (06) :897-902
[4]   EXPERIENCE WITH THE USE OF CEFOTAXIME IN THE TREATMENT OF BACTERIAL-MENINGITIS [J].
CHERUBIN, CE ;
ENG, RHK .
AMERICAN JOURNAL OF MEDICINE, 1986, 80 (03) :398-404
[5]   TREATMENT FAILURES OF CEFOTAXIME AND LATAMOXEF IN MENINGITIS CAUSED BY ENTEROBACTER AND SERRATIA SPP [J].
ENG, RHK ;
CHERUBIN, CE ;
PECHERE, JC ;
BEAM, TR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 (06) :903-911
[6]   EXAMINATION OF GRAM-NEGATIVE BACILLI FROM MENINGITIS PATIENTS WHO FAILED OR RELAPSED ON MOXALACTAM THERAPY [J].
ENG, RHK ;
CHERUBIN, C ;
SMITH, SM ;
BUCCINI, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (06) :850-856
[7]   CEFOTAXIME FOR TREATMENT OF GRAM-NEGATIVE BACTERIAL-MENINGITIS IN INFANTS AND CHILDREN [J].
FELDSTEIN, TJ ;
UDEN, DL ;
LARSON, TA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1987, 6 (05) :471-475
[8]   CEFOTAXIME - INVITRO ACTIVITY AND TENTATIVE INTERPRETIVE STANDARDS FOR DISK SUSCEPTIBILITY TESTING [J].
FUCHS, PC ;
BARRY, AL ;
THORNSBERRY, C ;
JONES, RN ;
GAVAN, TL ;
GERLACH, EH ;
SOMMERS, HM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (01) :88-93
[9]   EARLY SYNERGISTIC INTERACTIONS BETWEEN AMIKACIN AND 6 BETA-LACTAM ANTIBIOTICS AGAINST MULTIPLY RESISTANT MEMBERS OF THE FAMILY ENTEROBACTERIACEAE [J].
GLEW, RH ;
PAVUK, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (03) :378-381
[10]   CEFOTAXIME TREATMENT OF GRAM-NEGATIVE ENTERIC MENINGITIS IN INFANTS AND CHILDREN [J].
JACOBS, RF .
DRUGS, 1988, 35 :185-189